शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEUnjha Formulations Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 16 May, 2025 · 15:20 IST

APPOINTMENT OF SECRERTRAILA AUDITORS

Profit growth above 25%Negative operating cash flowResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.0%Reaction day
₹23.24
prior close
₹23.00
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-1.8% vs market
Pharmaceuticals peers, median of 150sector+0.2%-1.1% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.3
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.0+0.8-1.8+0.2-1.1
Next day
-3.9+2.0-5.9+1.1-5.1
2d
+2.8+0.9+1.9+0.1+2.7
3d
-1.2+1.7-2.8+1.0-2.2
4d
-3.1+1.6-4.7+1.2-4.3
5d
+1.1+2.2-1.1+0.7+0.4
1w
+1.1+2.7-1.6+1.4-0.3
15d
+4.3+4.5-0.2+0.6+3.7
1m
+3.3+5.6-2.3+2.1+1.2
2m
+21.3+9.0+12.4+3.8+17.5
3m
+6.2+3.5+2.6-1.0+7.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unjha Formulations Ltd's board, at its meeting on 16 May 2025, approved the audited financial results for Q4 and FY ended 31 March 2025. Revenue from operations stood flat at Rs. 1,849.06 lakhs versus Rs. 1,850.75 lakhs in FY24. Profit after tax rose to Rs. 40.76 lakhs from Rs. 27.79 lakhs in FY24, a growth of around 47%, though the company reported a loss of Rs. 40.64 lakhs in the standalone Q4 quarter. The statutory auditor (Jain & Golechha) issued an un-modified (clean) opinion with no Key Audit Matters flagged. The board also appointed M/s Ajay Parikh & Associates as Secretarial Auditor for a five-year term (FY26 to FY30), pending shareholder approval. The cash flow statement shows negative cash from operations of Rs. 10.43 lakhs for FY25.

Likely market impact

Clean audit opinion and improved annual PAT are positives, but flat revenue, a Q4 standalone loss, and negative operating cash flow may concern investors looking for growth and cash generation. The secretarial auditor appointment is routine governance and should have no material effect on shareholders.